Archive for the ‘Atypical_antipsychotics’ tag
Abilify
Abilify Canada
Voici Abilify, indiqu?© dans le traitement de la schizophr?©nie.
Parce que les sympt??mes n?©gatifs font aussi partie de la route.
Une att?©nuation des sympt??mes positifs et n?©gatifs a ?©t?© d?©montr?©e avec Abilify.
Nouveau Abilify.
Here's Abilify, indicated for the treatment of schizophrenia.
Because negative symptoms are also part of the road.
Mitigation of positive and negative symptoms has been demonstrated with Abilify.
New Abilify.
Aripiprazole (marketed as Abilify, Abilify Discmelt; also known as BMS 337039, OPC-14597, and APZ) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently, it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, and as an adjunct for the treatment of major depressive disorder. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.
Brand name: Abilify
Generic name/category: Aripiprazole, Atypical antipsychotics, Piperazines
Company: Bristol-Myers Squibb (BMS)
Country/Market: Canada, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Le M?©decin du Qu?©bec – September 2009
To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009
Visit AdPharm.net for more pharmaceutical ads
Geodon
Control acute agitation with Geodon for injection
In schizophrenia… Rapid improvement with low EPS
Ziprasidone (marketed as Geodon, Zeldox by Pfizer) was the fifth atypical antipsychotic to gain FDA approval (February 2001). In the United States, Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania and mixed states associated with bipolar disorder. The brand name Geodon has been suggested to bring to mind the phrase 'down (don) to earth (geo)' referring to the goals of the medication.
The oral form of ziprasidone is the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form, on the other hand, is the mesylate salt, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder.
From Wikipedia (text available under Creative Commons Attribution/Share-Alike License)
Brand name: Geodon
Generic name/category: Ziprasidone, Atypical antipsychotics
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration single-page
Publication/Aired: American College Of Emergency Physicians – April 2007
To see all of this brand's ads on AdPharm, click here
2 views
Aug 23, 2009
Visit AdPharm.net for more pharmaceutical ads
Geodon
Control acute agitation with Geodon for injection
In schizophrenia… Rapid improvement with low EPS
Ziprasidone (marketed as Geodon, Zeldox by Pfizer) was the fifth atypical antipsychotic to gain FDA approval (February 2001). In the United States, Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania and mixed states associated with bipolar disorder. The brand name Geodon has been suggested to bring to mind the phrase 'down (don) to earth (geo)' referring to the goals of the medication.
The oral form of ziprasidone is the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form, on the other hand, is the mesylate salt, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder.
From Wikipedia (text available under Creative Commons Attribution/Share-Alike License)
Brand name: Geodon
Generic name/category: Ziprasidone, Atypical antipsychotics
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration single-page
Publication/Aired: American College Of Emergency Physicians – April 2007
To see all of this brand's ads on AdPharm, click here
0 views
Aug 23, 2009
